———————————————————— ** http://bluehorseshestocks.com/images/shoeheader.png ———————————————————— ———————————————————— Lexaria Corp. LXRP Following our initial report on LXRP yesterday (http://bluehorseshoestocks.com/blue-horseshoe-stocks-lxrp-special-report/) , the stock had a productive session as it traded in a range from .095 to a high of .108, an intraday gain of 14% on roughly 2.5X the monthly average volume. It closed at .102 holding more than half of the day`s gains, which is generally a good sign.
We promised to relay any further updates regarding the current status of LXRP, and sure enough the company published a fresh PR this morning containing another major development. It relates to the sale of Lexaria`s domestic oil assets, which we mentioned in yesterday`s report, becoming final with all funds received. It provides LXRP with a cash infusion of $1.4M which will facilitate a clearing of all debt currently on the books, as well as advance the company`s plans to release a CBD-infused tea (infusion method is patent pending) via a new online sales portal. With the rate at which LXRP has been executing its strategies, we expect to hear about the opening of that website any day now.
KELOWNA, BC / ACCESSWIRE / December 10, 2014 / Lexaria Corp. (LXRP (http://finance.yahoo.com/qs=lxrp) ) (CSE:LXX) (the “Company” or “Lexaria”) is pleased to announce the sale of all its Belmont Lake oil assets for $1.4 million in cash has closed and all money received. Lexaria congratulates the new owners for having purchased a fine asset.>> FULL PR (http://finance.yahoo.com/news/lexaria-oilfield-sale-completed-130100045.html) ———————————————————— FDA-Related News We caught a couple of FDA news plays on this morning`s scan that we`ll want to keep an eye on:
ARCA BioPharma, Inc. ABIO has reported that the FDA “has granted orphan drug designation to rNAPc2 as a potential treatment of viral hemorrhagic fever post-exposure to Ebola virus.” >> VIEW PR (http://finance.yahoo.com/news/arca-biopharma-receives-fda-orphan-133000482.html) Cytori Therapeutics, Inc. CYTX announced that the FDA granted approval “for a pivotal clinical trial, named the ‘STAR’ trial, to evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma, a rare autoimmune disease affecting approximately 50,000 patients in the United States.” >> VIEW PR (http://finance.yahoo.com/news/fda-grants-cytori-conditional-approval-130000220.html) ———————————————————— Extended Watchlist:
** follow on Twitter (https://www.twitter.com/RadPennyStocks/) | ** friend on Facebook (#) | ** forward to a friend (http://us1.forward-to-friend.com/forwardu591e6119e16cf9ff528823d&id2054cae8&e=e2e65a0f0a) Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. ** Our disclaimer (http://bluehorseshoestocks.com/disclaimer) is to be read and fully agreed to before using our site, or joining our email list. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions, however any that may occur will be corrected as needed. BHS and its affiliates are not registered or licensed investment advisers, nor broker dealers. BHS cautions that the investments in companies profiled are commonly considered to be extremely high risk and use of any information provided is at the investor`s sole risk. 12/09/14 – Owners of this website received $2000USD from a Third-Party for a One Week Awareness Campaign on LXRP.
Copyright © 2014 Bullinadvantage.com, All rights reserved.
WE USE AND FULLY ENDORSE:
** EquityFeed (http://mbsy.co/3lQTF) CLICK TO SIGN UP TODAY! **